Sarepta Therapeutics, Inc.
215 First Street
Cambridge, MA -2142
United States
829 articles with Sarepta Therapeutics, Inc.
-
Sarepta Therapeutics to Announce Third Quarter 2021 Financial Results and Recent Corporate Developments on November 3, 2021
10/27/2021
Sarepta Therapeutics, Inc. will report third quarter 2021 financial results after the Nasdaq Global Market closes on Wednesday, November 3, 2021.
-
Clinical Catch-Up: October 11-15
10/18/2021
It was yet another busy week for clinical trial announcements. Take a look. -
Sarepta Therapeutics Announces Pricing of $500 Million Public Offering of Common Stock
10/14/2021
Sarepta Therapeutics, Inc., the leader in precision genetic medicine for rare diseases, announced that it has priced an underwritten public offering of 6,172,840 shares of its common stock at a price to the public of $81.00 per share.
-
Sarepta Therapeutics Announces Proposed $500,000,000 Public Offering of Common Stock
10/12/2021
Sarepta Therapeutics, Inc., the leader in precision genetic medicine for rare diseases, announced that it is offering to sell, subject to market and other conditions, $500,000,000 in shares of its common stock in an underwritten public offering.
-
Sarepta Therapeutics Announces Preliminary Financial Results for the Third Quar-ter Ended September 30, 2021
10/12/2021
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced preliminary financial results for its third quarter ended September 30, 2021.
-
Sarepta Therapeutics’ SRP-9001 Shows Sustained Functional Improvements in Multiple Studies of Patients with Duchenne
10/11/2021
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today shared new analyses and functional data from its SRP-9001 (rAAVrh74.MHCK7.micro-dystrophin) development program
-
Sarepta Therapeutics Announces Initiation of EMBARK, a Global Pivotal Study of SRP-9001, a Gene Therapy for the Treatment of Duchenne Muscular Dystrophy
10/4/2021
Sarepta Therapeutics, Inc., the leader in precision genetic medicine for rare diseases, announced the initiation, in partnership with Roche, in the U.S. and countries around the world, of study SRP-9001-301, also known as EMBARK, a pivotal study of SRP-9001 for the treatment of Duchenne muscular dystrophy.
-
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Sep 30, 2021
9/30/2021
Sarepta Therapeutics, Inc., the leader in precision genetic medicine for rare diseases, granted equity awards on September 30, 2021 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to employment to 43 individuals hired by Sarepta in September 2021.
-
Pfizer reported three cases of muscle weakness, two of which involved inflammation of the heart (myocarditis).
-
Sarepta Therapeutics to Initiate Part B of MOMENTUM Study of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping Following Positive Interactions with FDA
9/27/2021
Sarepta Therapeutics, Inc. today announced that following positive interactions with the U.S. Food and Drug Administration (FDA), the Company plans to initiate Part B of the MOMENTUM study (Study 5051-201), in the fourth quarter.
-
Sarepta Therapeutics to Showcase Data from its Gene Therapy and RNA Platforms at World Muscle Society 2021 Virtual Congress
9/14/2021
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will present at the World Muscle Society 2021 Virtual Congress (WMS 2021), taking place Sept. 20-24, 2021.
-
Selecta and Cyrus' partnership will pair Selecta’s immune-modulating ImmTOR platform with Cyrus’ ability to redesign protein therapeutics through its de novo computational approach.
-
Sarepta Therapeutics to Present at Upcoming Investor Conferences in September 2021
9/7/2021
Sarepta Therapeutics, Inc., the leader in precision genetic medicine for rare diseases, announced that senior management will participate in fireside chats at two upcoming virtual investor conferences.
-
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Aug 31, 2021
8/31/2021
Sarepta Therapeutics, Inc., the leader in precision genetic medicine for rare diseases, granted equity awards on August 31, 2021 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to employment to 11 individuals hired by Sarepta in August 2021.
-
Sarepta Therapeutics Executes Licensing Agreement for Gene Therapy Program from Nationwide Children’s Hospital to Treat Limb-Girdle Muscular Dystrophy Type 2A
8/4/2021
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that upon completion of a number of preclinical and safety studies, it had executed an exclusive license agreement for an investigational gene therapy candidate, calpain 3 (CAPN-3), to treat Limb-girdle muscular dystrophy type 2A (LGMD2A), developed by the Abigail Wexner Research Institute at Nationwide Children’s Hospital (Nationwide Children’s).
-
Sarepta Therapeutics Announces Second Quarter 2021 Financial Results and Recent Corporate Developments
8/4/2021
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the second quarter of 2021.
-
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - July 30, 2021
7/30/2021
Sarepta Therapeutics, Inc., the leader in precision genetic medicine for rare diseases, granted equity awards on July 30, 2021 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to employment to 10 individuals hired by Sarepta in July 2021.
-
Sarepta Therapeutics to Announce Second Quarter 2021 Financial Results and Recent Corporate Developments on August 4, 2021
7/28/2021
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report second quarter 2021 financial results after the Nasdaq Global Market closes on Wednesday, August 4, 2021.
-
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - June 30, 2021
6/30/2021
Sarepta Therapeutics, Inc., the leader in precision genetic medicine for rare diseases, granted equity awards on June 30, 2021 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to employment to 2 individuals hired by Sarepta in June 2021.